Clinical Study About Tinglidazaoxiefeitang And Zhenwutang To Treat The Chronic Heart Failure Patients Of Heart Kidney Yang Deficiency Type

Objective Observe the curative effect and safety that the TINGLIDAZAOXIEFEITANG and ZHENWUTANG treat cases of heart kidney Yang deficiency type of chronic heart failure,and plans for clinical treatment of chronic heart failure treatment to provide practical and valuable.Methods According to include and exclude the standard, selected 60 cases of heilongjiang Chinese medicine academy of sciences, nangang Cardiology The second ward outpatient and hospitalized cases, and divided them into trial group and control group by using prospective randomized controlled study. There are no statistical difference of two groups of patients with general data. Control group used QILIQIANGXIN capsule,the experimental group plused TINGLIDAZAOXIEFEITANG and ZHENWUTANG on the basis of conventional western medicine therapy, and oral warmly in half an hour after breakfast and dinner, one dose a day, twice a day,We assessed the clinical curative effect after 4 weeks. Systematically observed and compared the two groups of patients before and after treatment of traditional Chinese medicine syndrome integral,cardiac function classification of heart failure,left ventricular ejection fraction.Observe two groups of patients the change of the blood,urine and stool before and after treatment.Results After four weeks, therapy clinical studies confirmed that the experimental group in the cardiac function, lee’s integral, integral effect of lee’s heart failure and heart failure syndromes total curative effect is better than that in control group(P < 0.05); Experimental group in the tongue, tongue coating, pulse condition of improvement is better than that of control group(P < 0.05); Experimental group echocardiography results that increase left ventricular ejection fraction(LVEF) is obviously better than that of control group(P < 0.05);Patients plasma NT- pro BNP(N terminal brain peptide precursor) value of the reduction is better than control group(P < 0.05);Experimental group and control group had no obvious change of liver and kidney function, blood routine, routine urine routine before and after the treatment(P > 0.05).Conclusion The TINGLIDAZAOXIEFEITANG and ZHENWUTANG can improve the clinical symptoms of patients with CHF, and improve the quality of life, its security is very good, and it is worth further research and extension.